Get Your 7-Day Free Trial! Start Now!
Get Premium to unlock powerful stock data
NAS:IONS (USA)  
Manual of Stocks™
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc

$ 37.94 +0.923 (+2.49%) 03:45 PM EST
Warning! GuruFocus has detected 1 Severe warning sign with IONS. Subscribe to check it out.
P/E:
At Loss
P/B:
7.57
Market Cap:
$ 5.38B
Enterprise V:
$ 4.40B
Volume:
457.93K
Avg Vol (2M):
1.06M
Also Trade In:
Volume:
457.93K
Market Cap $:
5.38B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.06M
Enterprise Value $:
4.40B
PB Ratio:
7.57
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Ionis Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
https://www.ionispharma.com
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Compare
Compare
NAS:CRSP • NAS:ASND • NYSE:DNA • NAS:APLS • NAS:ALKS • NAS:HALO • NAS:SRPT • NAS:RARE • NAS:CERE • NAS:NTLA • OCSE:NOVO B • ASX:CSL • NAS:VRTX • NAS:REGN • NAS:MRNA • XKRX:207940 • HKSE:02269 • NAS:SGEN • NAS:BNTX • SZSE:300122
Traded in other countries / regions
ISI.Germany • IONS.Mexico • IONS.Switzerland • 0JDI.UK • IONS.USA
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Financial Strength

6/10
Name Current Vs Industry Vs History
Cash-To-Debt 1.68
Equity-to-Asset 0.28
Debt-to-Equity 1.72
Debt-to-EBITDA 64.98
Interest Coverage 5.83
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.36
Distress
Grey
Safe
Beneish M-Score -2.4
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

9/10
Name Current Vs Industry Vs History
5-Day RSI 43.38
9-Day RSI 50.59
14-Day RSI 51.03
6-1 Month Momentum % 20.01
12-1 Month Momentum % -8.45

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.86
Quick Ratio 9.76
Cash Ratio 8.98
Days Inventory 693.22
Days Payable 355.52

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.8

Financials (Next Earnings Date:2022-08-04 Est.)

IONS's 30-Y Financials

Guru Trades

See Details
To
EMBED
 SAVE

Insider Trades

See Details
To
EMBED
 SAVE

Gurus Latest Trades with NAS:IONS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
 SAVE
Dividend
To
EMBED
 SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

GF Value: $44.5
IONS
EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 840.768
EPS (TTM) ($) -0.2
Beta 0.67
Volatility % 33.66
14-Day RSI 51.03
14-Day ATR ($) 1.626511
20-Day SMA ($) 36.0615
12-1 Month Momentum % -8.45
52-Week Range ($) 25.04 - 44.42
Shares Outstanding (Mil) 141.8

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ionis Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More
Get Premium to unlock powerful stock data
Product
Home
Site Map
Mobile App
Email Alerts
中文
Business
Advertise
Referral Program
Affiliate Program
Information
Career
RSS
FAQ
Contact Us
About
About Us
ADV Part 2A
ADV Part 2B
ADV Part 3
Term of Use
Privacy Policy
Affiliate Program
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.